Patent Application
20220054493
This invention relates to compounds that are inhibitors of NGAL activity, and applications thereof.
Neutrophil Gelatinase-Associated Lipocalin (NGAL) (also known as lipocalin-2, oncogene 24p3, siderocalin or uterocalin) is a small circulating protein induced in a wide variety of pathological situations. Initially, NGAL has been identified in mature neutrophil granules. It has also been discovered that NGAL was expressed in the kidney, prostate, and epithelia of the respiratory and alimentary tracts. In particular, NGAL is expressed in many other cell types such as in renal, endothelial, liver and smooth muscle cells, but also in cardiomyocytes, neurons and in different populations of immune cells such as macrophages and dendritic cells. Studies have highlighted the implication of NGAL in renal injuries or its role as inflammation biomarker. Other researches demonstrated that NGAL has a link with growth factor, a role in iron trafficking, chemotactic and bacteriostatic effects, as well as activities such as differentiation, proliferation and inflammation. For example, NGAL participates to the epithelial-mesenchymal transition in vivo in a pulmonary adenocarcinoma model and in vitro in prostate and breast cancer cells. In these models, NGAL promoted the motility, invasiveness and metastatic capacities of cancer cells. NGAL is also involved in cardiovascular, metabolic and renal diseases. For example, gene inactivation in mice blunted the pathophysiological consequences of cardiovascular (myocardial infarction or ischemia), renal (subtotal nephrectomy) or metabolic (High Fat Diet) challenges.
There is thus a need to found NGAL inhibitors which can be used as therapeutic agents since NGAL protein is involved in various diseases.
The present inventors have found compounds which can be used as NGAL inhibitors and thus can be used in the treatment and/or prevention of NGAL involved diseases.
The present invention relates to the use of a compound of general formula (I) as a NGAL inhibitor:
wherein
R1 represents:
R2 represents an aryl group optionally substituted by one or more:
The present invention also relates to the use of a compound of general formula (II) as a NGAL inhibitor:
wherein:
X1 represents a nitrogen atom, or a carbon atom;
X2 represents a carbon atom, or a CH group;
X3 represents a nitrogen atom;
X4 represents an oxygen atom, or a carbon atom;
X5 represents a carbon atom, or a nitrogen atom;
R5 represents:
R6 represents a phenyl group, a lone pair, an oxygen atom, or an halogeno atom;
R9 represents a ═NH group, or a lone pair;
R7 and R8 represent a lone pair or R8—X4—X3—R7 optionally form a six membered ring heterocycle, said heterocycle being optionally substituted by one or more methyl groups, preferably by two methyl groups.
The present invention also relates to the use of a compound of general formula (III) as a NGAL inhibitor:
wherein
R13 represents
R14 represents a lone pair, a hydrogen atom or an halogen atom;
R15 represents a methyl group, a hydrogen atom or a lone pair; and
R16 represents a methyl group, a hydrogen atom or a lone pair.
As used herein, the term “NGAL” has its general meaning in the art and refers to the Neutrophil Gelatinase-Associated Lipocalin as described in Schmidt-Ott K M. et al. (2007) (Schmidt-Ott K M, Mori K, Li J Y, Kalandadze A, Cohen D J, Devarajan P, Barasch J. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007 February; 18(2):407-13. Epub 2007 Jan. 17. Review.). NGAL was shown to exist both as a 25-kDa monomer and a 45-kDa disulfide-linked homodimer, and it may also be covalently complexed with neutrophil gelatinase (also known as matrix metalloproteinase 9, MMP-9) via an intermolecular disulphide bridge as a 135-kDa heterodimeric form.
An “inhibitor of NGAL activity” has its general meaning in the art, and refers to a compound (natural or not) which has the capability of reducing or suppressing the activity of NGAL. For example the compound may block the interaction of NGAL with the NGAL binding ligands, or may bind to NGAL in manner that NGAL losses its capacity to interact with its receptors (for example 24p3R, megalin, SLC22A17 Solute carrier family 22 member 17) or with other proteins (for example the metalloprotease MMP9), thereby modifying the NGAL-mediated signalling.
In the present invention, the wording “inhibitor of NGAL activity” and “NGAL inhibitor” have the same meaning.
Typically, the inhibitory activity of an NGAL inhibitor as defined in the present invention is evaluated on the NGAL-induced IL6 secretion. In particular, an NGAL inhibitor as defined in the present invention is able to prevent the increase of IL-6 production and secretion induced by NGAL in primary culture of human cardiac fibroblasts.
Without wishing to be bound by theory, the “NGAL inhibitor” as defined in the present invention may refer to an inhibitor which inhibits the interaction of the NGAL with its receptor based on NGAL surface cavities. These hot-spots may be putative protein-protein contact interfaces between NGAL and its cognate receptor and the NGAL inhibitor may disrupt the corresponding interactions.
The present invention relates to the use of a compound of general formula (I) as a NGAL inhibitor:
wherein:
R1 represents:
R2 represents an aryl group optionally substituted by one or more:
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 and R2 represents an aryl group substituted by —C≡N is excluded.
In a particular embodiment, a compound wherein R2 represents an aryl group substituted by —NH2 and R1 represents (CH2)n2-aryl wherein n2 is 1 is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n1-pyrazole substituted by a pyridinyl group wherein n1 is 0 and R2 represents an aryl group substituted by —C≡N is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 or 1 and R2 represents an aryl group, an aryl group substituted by —C≡N or an aryl group substituted by —NH2 is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 substituted by a pyrazolyl group and R2 represents an aryl group substituted by —C(═O)—R4 wherein R4 represents a methyl group is excluded.
In a particular embodiment, a compound wherein R1 represents —C(═O)—N(H)—R3 wherein R3 represents a cyclohexyl group and R2 represents an aryl group substituted by —C(═O)—R4 wherein R4 represents a methyl group is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 and R2 represents an aryl group substituted by —C(═O)—R4 wherein R4 represents a methyl group is excluded.
In a particular embodiment, the compound of formula (I) is selected from the group consisting of:
In a particular embodiment, the compound of formula (I) is selected from the group consisting of:
The present invention also relates to the use of a compound of general formula (I) as a NGAL inhibitor:
wherein
R1 represents:
R2 represents an aryl group optionally substituted by one or more:
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 and R2 represents an aryl group substituted by —C≡N is excluded.
In a particular embodiment, a compound wherein R2 represents an aryl group substituted by —NH2 and R1 represents (CH2)n2-aryl wherein n2 is 1 is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n1-pyrazole substituted by a pyridinyl group wherein n1 is 0 and R2 represents an aryl group substituted by —C≡N is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 or 1 and R2 represents an aryl group, an aryl group substituted by —C≡N or an aryl group substituted by —NH2 is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 substituted by a pyrazolyl group and R2 represents an aryl group substituted by —C(═O)—R4 wherein R4 represents a methyl group is excluded.
In a particular embodiment, a compound wherein R1 represents (CH2)n2-aryl wherein n2 is 0 and R2 represents an aryl group substituted by —C(═O)—R4 wherein R4 represents a methyl group is excluded.
In a particular embodiment, the compound of general formula (I) is selected from the group consisting of:
In a particular embodiment, the compound of general formula (I) is selected from the group consisting of:
The present invention also relates to the use of a compound of general formula (II) as a NGAL inhibitor:
wherein:
X1 represents a nitrogen atom, or a carbon atom;
X2 represents a carbon atom, or a CH group;
X3 represents a nitrogen atom;
X4 represents an oxygen atom, or a carbon atom;
X5 represents a carbon atom, or a nitrogen atom;
R5 represents:
R6 represents a phenyl group, a lone pair, an oxygen atom, or an halogeno atom;
R9 represents a ═NH group, or a lone pair;
R7 and R8 represent a lone pair or R8—X4—X3—R7 optionally form a six membered ring heterocycle, said heterocycle being optionally substituted by one or more methyl groups, preferably by two methyl groups.
In a particular embodiment, a compound wherein:
X1 represents a carbon atom;
X2 represents a carbon atom;
X3 represents a nitrogen atom;
X4 represents a carbon atom;
X5 represents a carbon atom;
R5 represents CH2—S—R10,
R6 represents a lone pair;
R9 represents a lone pair;
R8—X4—X3—R7 optionally form a six membered ring heterocycle substituted by one methyl group, is excluded.
In a particular embodiment, a compound wherein:
X1 represents a nitrogen atom;
X2 represents a carbon atom;
X3 represents a nitrogen atom;
X4 represents an oxygen atom;
X5 represents a carbon atom;
R5 represents (CH2)n4-N(—C2H5)(—C2H5) wherein n4 is equal to 2,
R6 represents a phenyl group;
R9 represents a ═NH group;
R7 and R8 represent a lone pair, is excluded.
In a particular embodiment, a compound wherein:
X1 represents a carbon atom;
X2 represents a carbon atom;
X3 represents a nitrogen atom;
X4 represents a carbon atom;
X5 represents a nitrogen atom;
R5 represents CH2—S—R10,
R6 represents a lone pair;
R9 represents a lone pair;
R8—X4—X3—R7 optionally form a six membered ring heterocycle, is excluded.
In a particular embodiment, the compound of general formula (II) is selected from the group consisting of:
The present invention also relates to the use of a compound of general formula (III) as a NGAL inhibitor:
wherein
R13 represents
R14 represents a lone pair, a hydrogen atom or an halogen atom;
R15 represents a methyl group, a hydrogen atom or a lone pair; and
R16 represents a methyl group, a hydrogen atom or a lone pair.
In a particular embodiment, the inhibitor is selected from the group consisting of:
3-acetyl-N-[2-(1H-pyrazol-1-yl)phenyl]methyl]-benzenesulfonamide has been synthetized according to the following scheme.
To a solution of [2-(1H-pyrazol-1-yl)phenyl]methylamine (3.0 g) in pyridine (20 mL) was slowly added 3-acetylbenzylsulfonyl chloride (4.17 g) at 0° C., and the mixture was stirred overnight at 115° C. After cooling down, the reaction solution was concentrated under reduced pressure. The residue was then dissolved in dichloromethane, washed with HCl 2 N, a saturated aqueous solution of NaHCO3 and saturated brine, then dried over magnesium sulfate, and concentrated under reduced pressure. The residue was finally purified by flash column chromatography (1:1 EtOAc/petroleum ether) to give the title compound as a white solid (5.72 g, 93% yield). 1H NMR (400 MHz, CDCl3) δ 8.27 (t, J=1.6 Hz, 1H), 8.01 (dt, J=1.6 and 8.0 Hz, 1H), 7.96 (dt, J=1.6 and 8.0 Hz, 1H), 7.69 (d, J=1.2 Hz, 1H), 7.63 (d, J=2.4 Hz, 1H), 7.48 (t, J=8.0 Hz, 1H), 7.30-7.26 (m, 2H), 7.18-7.14 (m, 2H), 6.45 (t, J=2.2 Hz, 1H), 4.08 (d, J=6.4 Hz, 2H), 2.55 (s, 3H).
Other compounds are commercialized by Ambinter:
GPZ478519 (CAS: 1171056-55-5)
GPZ505884 (CAS: 1170422-94-2)
GPZ595600 (CAS: 1355610-80-8)
GPZ624624 Sulfaphenazole (CAS: 526-08-9)
GPZ642292 (CAS: 1088151-90-9)
GPZ706277 Acetohexamide (CAS: 968-81-0)
GPZ778195 (CAS: 1355676-34-4)
GPZ863205 (CAS: 1797184-54-3)
GPZ913629 (CAS: 1223268-60-7)
GPZ058225 (CAS: 519050-14-7)
GPZ278618 (CAS: 1375221-88-7)
GPZ519431 (CAS: 683784-46-5)
GPZ564849 (CAS: 300696-62-2)
GPZ646083 Imolamine (CAS: 318-23-0)
GPZ743042 (CAS: 314746-74-2)
The present invention also relates to a method for inhibiting NGAL activity by using the compound as previously defined in the presence of a NGAL protein.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
According to one embodiment, the present invention relates to a therapeutic use of the method as defined above.
In another embodiment, the present invention relates to non-therapeutic use of the method as defined above.
It is known from the prior art that NGAL protein is involved in several diseases.
The present inventors have found and demonstrated the inhibitory activity of compounds as previously defined towards NGAL protein. Accordingly, it will be acknowledged that the compounds as previously defined, which are NGAL inhibitors, can be used for treating NGAL induced diseases.
The present inventors have found that the compounds as defined in the present invention can be used as therapeutic agents.
Thus, the present invention relates to the compound as previously defined for use in a therapeutic method for inhibiting the NGAL activity.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for its use as a medicament.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
The present invention also provides a pharmaceutical composition comprising, as active principle, the compound as previously defined and a pharmaceutically acceptable excipient.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
The term “pharmaceutical composition” in the present invention refers to any composition comprising compound of formula (I), the compound of formula (II) or the compound of formula (III) as previously defined and at least one pharmaceutically acceptable excipient. By the term “pharmaceutically acceptable excipient” herein, it is understood a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredient(s) and which is not excessively toxic to the host at the concentration at which it is administered. Said excipients are selected, depending on the pharmaceutical form and the desired method of administration, from the usual excipients known by a person skilled in the art.
In particular, the compound as previously defined can be used for treating NGAL induced diseases.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention also relates to the compound as previously defined for the manufacture of a medicament for the prevention or treatment of a NGAL induced disease.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
By “NGAL induced diseases” it is understood diseases mediated by the NGAL protein. It is well-known that diseases mediated by the NGAL protein refer to any disease where the NGAL protein plays a role.
As used herein “NGAL induced diseases” refers to a specific form of disease wherein the NGAL contributes to the development of the disease and thus refers to a particular sub-type of diseases.
Typically, to know if the disease to be treated or prevented is a NGAL induced disease, the expression and/or activity of NGAL protein can be measured using ELISA, western-blot or any quantitative protein or gene expression methods. A particular increase of NGAL expression/activity in tissues, cells or body fluids will indicate that NGAL contribute to the development of a particular sub-type of diseases.
According to the present invention, by treating NGAL induced diseases it is also understood preventing NGAL induced diseases. Indeed, by treating a disease associated with the presence of NGAL protein, it is possible to prevent a disease or a trouble linked to the presence of NGAL protein.
Thus, in particular, the compound as previously defined can be used for preventing NGAL induced diseases.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Another object of the present invention relates to a method of treating a NGAL induced disease, comprising administering to a patient in need thereof, an effective amount of a compound as previously defined, or of a pharmaceutical composition comprising said compound.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Another object of the present invention relates to a method of preventing a NGAL induced disease, comprising administering to a patient in need thereof, an effective amount of a compound as previously defined, or of a pharmaceutical composition comprising said compound.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
By “an effective amount” is meant a sufficient amount of the compound of formula (I), the compound of formula (II) or the compound of formula (III) to treat or to prevent the NGAL induced disease.
Suitable dosage ranges depend upon numerous factors such as the severity of the disease to be treated, the age and relative health of the subject, the route and the form of administration.
According to the present invention, the compound of formula (I), the compound of formula (II) or the compound of formula (III) may be administered alone or in combination with other drugs well known by a person skilled in the art.
Typically, the patient may be a human or another mammal (e.g., primate, mouse, rat, rabbit, dog, cat, horse, cow, pig, camel, and the like). Preferably, the patient is a human.
In a particular embodiment, NGAL induced diseases are cardiovascular diseases.
The role of NGAL in cardiovascular diseases or troubles has been studied in:
a) Heart failure, and in particular hypertrophic heart failure:
b) Abdominal aortic aneurysm:
c) Ischemia reperfusion in transplanted heart, cardiac ischemia reperfusion, besides transplantation:
d) Atherosclerosis:
As disclosed in WO 2012/072820 A1, inhibitors of NGAL gene expression or NGAL antagonists may be used in the prevention or the treatment of heart failure.
The term “heart failure” (HF) as used herein embraces congestive heart failure and/or chronic heart failure. Functional classification of heart failure is generally done by the New York Heart Association Functional Classification (Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis, 6th ed. Boston: Little, Brown and co, 1964; 114). This classification stages the severity of heart failure into 4 classes (I-IV). The classes (I-IV) are:
WO 2013/156867 A1 discloses that inhibitors of NGAL activity or gene expression may be used in the prevention or in the treatment of hypertension including arterial hypertension, venous hypertension and pulmonary hypertension.
WO 2014/049152 A1 relates to an in inhibitor of NGAL activity or gene expression for use in a method for treating or preventing cardiovascular fibrosis.
Thus, the present invention relates to the compound as previously defined for use in the treatment of heart failure, cardiac infarct, hypertension, cardiovascular fibrosis, atherosclerosis, cardiac ischemia-reperfusion injury, abdominal aortic aneurysm in a patient.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention also relates to the compound as previously defined for use in the prevention of heart failure, cardiac infarct, hypertension, cardiovascular fibrosis, atherosclerosis, cardiac ischemia-reperfusion injury, abdominal aortic aneurysm in a patient.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
According to the present invention, hypertension includes arterial hypertension, venous hypertension and pulmonary hypertension.
The term “hypertension” may also refer to arterial hypertension associated with chronic renal failure and/or to arterial hypertension and/or salt induced hypertension.
Thus, the present invention relates to the compound as previously defined for use in the prevention of heart failure in a patient.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, the NGAL induced diseases are renal diseases.
The role of NGAL in renal diseases or troubles has been studied in:
Typically, renal diseases are chronic kidney diseases, renal ischemia-reperfusion injury, aldosterone-induced renal injury, renal fibrosis, and antibody-mediated nephritis.
Thus, the present invention relates to the compound as previously defined for use in the treatment of renal diseases including chronic kidney diseases, renal ischemia-reperfusion injury, aldosterone-induced renal injury, renal fibrosis and antibody-mediated nephritis.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for use in the prevention of renal diseases including chronic kidney diseases, renal ischemia-reperfusion injury, aldosterone-induced renal injury, renal fibrosis and antibody-mediated nephritis. According to the present invention, renal injury includes inflammation and renal dysfunction.
According to the present invention, “renal fibrosis” may refer to renal interstitial fibrosis associated with chronic renal failure.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, NGAL induced diseases are associated to metabolism and obesity.
The role of NGAL in metabolism and obesity has been studied in:
Thus, the present invention relates to a compound as previously defined for use in the treatment of obesity and diabetes, insulin resistance associated to aging, endothelial dysfunction associated with dietary obesity.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to a compound as previously defined for use in the prevention of obesity and diabetes, insulin resistance associated to aging, endothelial dysfunction associated with dietary obesity.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, NGAL induced diseases are cancer.
The role of NGAL in cancer has been studied in:
Typically, cancer includes lung cancer, breast cancer, prostate cancer, pancreatic cancer, and chronic myeloid leukemia.
Thus, the present invention relates to the compound as previously defined for use in the treatment of cancer including lung cancer, breast cancer, prostate cancer, pancreatic cancer and chronic myeloid leukemia.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for use in the prevention of cancer including lung cancer, breast cancer, prostate cancer, pancreatic cancer and chronic myeloid leukemia.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, NGAL induced diseases are inflammatory diseases.
The role of NGAL in inflammatory diseases has been studied in:
Thus, the present invention relates to the compound as previously defined for use in the treatment of inflammatory diseases including intestinal inflammation, retinal diseases, systemic sclerosis, and encephalomyelitis.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for use in the prevention of inflammatory diseases including intestinal inflammation, retinal diseases, systemic sclerosis, and encephalomyelitis.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, NGAL induced diseases are linked to neuroprotection troubles.
The role of NGAL in neuroprotection troubles has been studied in:
Thus, the present invention relates to the compound as previously defined for use in the treatment of Parkinson, Alzheimer, vascular dementia, stoke, transient ischemic event, traumatic brain injury, neuropathic pain, and optic nerve neuritis.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for use in the prevention of Parkinson, Alzheimer, vascular dementia, stoke, transient ischemic event, traumatic brain injury, neuropathic pain, and optic nerve neuritis.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In a particular embodiment, NGAL induced diseases are liver diseases.
The role of NGAL in liver diseases has been studied in:
Thus, the present invention relates to the compound as previously defined for use in the treatment of alcoholic fatty liver diseases.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Thus, the present invention relates to the compound as previously defined for use in the prevention of alcoholic fatty liver diseases.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In particular, the compound as previously defined can be used for the treatment of a wound and in particular a chronic wound. Also, the compound as previously defined can be used for the treatment of a delayed wound closure.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
In particular, the compound as previously defined can be used for the prevention of a wound and in particular a chronic wound. Also, the compound as previously defined can be used for the prevention of a delayed wound closure.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
By “chronic wound” or “delayed wound closure” it is understood a wound that does not heal in an orderly set of stages and in a predictable amount of time.
Typically, wounds that do not heal within three months are considered chronic. Examples of chronic wounds include, but are not limited to, venous stasis ulcers, diabetic ulcers such as diabetic foot ulcers, and the like. Chronic, wounds may also include those relating to trauma or repeated trauma, thermal injury (e.g., burns) and radiation damage. In some embodiments, the treatment of chronic wound in a subject suffering from sickle-cell disease is also encompassed. In some embodiments, the treatment of chronic wound in elderly persons is also encompassed.
Another object of the present invention relates to a method of treating a wound, in particular a chronic wound, and a delayed wound closure, comprising applying to the skin subject an effective amount of a compound as previously defined, or a pharmaceutical composition comprising said compound.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
Another object of the present invention relates to a method of preventing a wound, in particular a chronic wound, and a delayed wound closure, comprising applying to the skin subject an effective amount of a compound as previously defined, or a pharmaceutical composition comprising said compound.
Preferably, the compound is a compound of formula (I) as previously defined.
Preferably, the compound is a compound of formula (II) as previously defined.
Preferably, the compound is a compound of formula (III) as previously defined.
By “an effective amount” is meant a sufficient amount of the compound of formula (I), the compound of formula (II) or the compound of formula (III) to treat or to prevent the wound, in particular the chronic wound, and the delayed wound closure.
Suitable dosage ranges depend upon numerous factors such as the severity of the wound to be treated, the age and relative health of the subject, and the form of the pharmaceutical composition.
According to the present invention, the compound of formula (I), the compound of formula (II) or the compound of formula (III) may be applied on the skin of the subject alone or in combination with other drugs well known by a person skilled in the art.
Typically, the subject may be a human or another mammal (e.g., primate, mouse, rat, rabbit, dog, cat, horse, cow, pig, camel, and the like). Preferably, the patient is a human.
Typically, the subject may suffer of a venous stasis ulcer, diabetic ulcer such as diabetic foot ulcer, trauma or repeated trauma, thermal injury such as burn, radiation damage and sickle-cell disease.
Although the exemplary embodiments of the present invention have been disclosed for illustrative purposes, a person skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
The present invention will now be illustrated using the following examples and figures, which are given by way of illustration, and are in no way limiting.
Prior to the virtual screening on NGAL, a database of compounds for virtual screening was prepared and the feasibility of in silico screening models for NGAL inhibitors was studied.
(i) Database of Compounds for Virtual Screening
More than 100 suppliers of chemical molecules were contacted for their catalogues to enrich the www.ambinter.com database. The aim is to have access to molecules, as much as possible, for future virtual and real screening. These chemical catalogues are usually in different formats which are not directly exploitable. A procedure to “normalize” the structures to be in the database was developed: discard radioactive, metallic, metalloid products, reactive products, pan-assay interference compounds, separate salts from main compounds, normalize the informatic representation of chemical structures (aromatization, ionic states etc.), calculate the 3D structure of each compounds. For natural compounds there can be specific problems such as fused rings or missing chirality information. In that case, the most probable configurations according to their internal energies was calculated. Unity molecular fingerprints (which can be seen as bar-codes that identify molecules) were calculated for the molecules for subsequent diversity or similarity searches. Subsets of the database consisting in natural products, drug-like molecules, lead-like molecules and molecules interfering with protein-protein interaction were also built.
(ii) In Silico Screening Models for NGAL Inhibitors
There are 2 possibilities to build protein models for virtual screening. If the structure of co-crystallised ligand-protein complex exists then the co-crystallised ligand can be used to calibrate the virtual screening software (the in silico prediction of how the ligand binds to the protein must fit with the X-ray data). If no structure is available, the target structure can be modeled by homology (for example find a homologue with a known 3D structure and use it as a template). The search of relevant homologue is performed with Fugue and the building of the molecule structure with Orchestrar within Sybyl package (Tripos, Mo., USA).
NGAL is an iron transporter and a signaling protein. Several crystal structures of NGAL with siderophores are published in the Protein Data Bank (e.g. PDB accession codes: 1DFV, 1NGL, etc.). By examining these 3D structures with or without siderophores, it is clear that the general 3D structure of the protein does not change. Therefore targeting the “main” binding site of siderophores may not exert significant effects though this cannot be rule out. The biological activity of NGAL in the context of MIF may be related to its interactions with a receptor. As NGAL receptor could not be modelled (no crystallographic data and no reliable homologue with a known 3D structure), the chosen strategy was to block the interaction of NGAL with its receptor by identifying putative protein-protein interaction (PPI) disruptors. Based on the 3D structure of NGAL, potential “hot spots” (i.e. residues important for PPI) on the protein surface were identified.
2 peripheral sites that may be PPI zones and be druggable were identified. Virtual screening was used to select potential disruptors of NGAL-NGAL receptor interaction. It consists in simulating the binding energy of a small molecule with NGAL binding sites. Since there are significant differences between NMR and X-ray 3D structures of NGAL (RMSD=4.6 Å calculated according to the backbone of 1DFV and 1NGL), it was necessary to use these 2 structures as templates for modelling NGAL.
Cell Culture Human cardiac fibroblasts (primary culture) were obtained from Promocell and maintained in medium (Fibroblast Media 3). Cells were cultured according to the manufacturer's instructions and used between passages 5 and 7. Cells were stimulated with aldosterone (10-8 M, Sigma) or recombinant hNGAL (500 ng/mL, R&D Systems) for 24 h for protein analysis. Mouse kidney fibroblasts (MKF), were isolated from Wild Type (WT) mice. Briefly, mice 7 to 8 weeks were sacrificed by cervical dislocation and kidneys were cleaned and rinsed in cold DPBS (Dulbecco's Phosphate-Buffered Saline). The renal cortex was minced and incubated in Dulbecco's modified eagle medium/Nutrient mixture F-12 (DMEM/F12, Sigma) containing 1 mg/mL collagenase A (Roche) during 25 minutes at 37° C. The digestion was inactivated by adding culture medium (DMEM/F12+10% FBS) then the cell suspension was passed through a 100-μm cell strainer. After centrifugation, the pellet (containing MKF) was diluted with culture medium then plated in 75 cm2 culture flask. After 24 hours MKF were washed with DPBS before replacement of fresh culture medium. Thereafter, culture medium was changed every 48 hours. Once 70-80% confluent, MKF were trypsinized and plated in 12 or 6-well plates. For experimental use, MKF were starved with culture medium containing only 3% FBS. MKF were treated with mNGAL (500 ng/mL, R&D Systems) for 24 h for gene expression analysis.
Two specific toxicity assays have been performed to assess hepatoxicity and cardiotoxicity. Hepatotoxicity was evaluated in isolated hepatocytes from swiss mice and determined by the MTT colorimetric assay. Cardiotoxicity was evaluated using the commercially available Predictor hERG fluorescence polarization kit (Thermo Fisher Scientific). Several ADME assays have been carried out on the compounds generated throughout the project. The following experiments were undertaken: Stability in human microsomes, binding to human plasma protein, and CYP3A4 inhibition assay (Vivid CYP3A4 assay, Thermo Fisher Scientific). Physico-chemical properties were also assessed such as aqueous solubility and chemical stability.
The Caco-2 Permeability assay uses an established method for predicting the in vivo absorption of drugs across the gut wall. The transport rate across the CaCo2 cell line is measured. This cell line has a human colon carcinoma origin and resembles to the intestinal epithelia (a polarised monolayer with microvilli and intercellular tight junctions).
Bidirectional transport (apical to basolateral (A-B) and basolateral to apical (B-A)) across the cell monolayer were determined allowing to calculate the efflux ratio (an indicator as to whether a compound undergoes active efflux).
8-12 weeks old mice (WT C57B16 for GP1 compound experiments) or 8-12 weeks old mice with genetic inactivation of lcn2 (as described in Martinez-martinez et al., Hypertension 2017, December; 70(6):1148-1156) have been used. LV diastolic and systolic diameters were measured in anesthetized (isofluorane 1.5%) mice, according to the American Society of Echocardiography's leading-edge method (using Vivid 7 echograph a 14 Mhz probe). In addition, LV outflow velocity was measured by pulsed waves, and CO was calculated as follows: CO=aortic VTI×[πx·(LV outflow diameter/2)2]×heart rate, where VTI is velocity-time integral.
LV hemodynamic was assessed as described previously.
Mice were anesthetized (chloral 320 mg·kg−1, IP) and the carotid artery cannulated with a pressure-volume catheter (SPR839, Millar-Instruments, USA) and the catheter was advanced into the LV. Pressure-volume loops were obtained at baseline and during loading by gently occluding the abdominal aorta. LV end-systolic and end-diastolic pressures, dP/dtmax/min, LV relaxation constant tau and were measured/calculated with IOX software (EMKA, France).
Systolic BP was measured by tail-cuff plethysmography in trained conscious mice at weeks 8-10 using a BP2000 Visitech model. BP was measured every day in the same room at the same hour for 5 consecutive days. The BP measurements (expressed as mmHg) presented are the averages of the last 3 days
Chronic kidney disease (CKD) was induced by subtotal nephrectomy (Nx) in eight-weeks-old FVB male mice (25-26 g). All surgeries were performed under ketamine/xylazine anaesthesia. Briefly, the left kidney was exposed, and the upper and lower poles were tied with a poly-glycolic acid suture line. The peritoneum and skin were then sutured, and the animals were returned to their individual cages. After one week of recovery, the second kidney was removed. Removal of the second kidney represents TO. Sham mice were subjected to the same surgical procedures but neither renal poles nor the right kidney were removed. Mice were monitored for any sign of distress, and those observed to be experiencing severe, unrelievable pain were euthanized. Renal failure was assessed by the measure of plasma creatinine and urea with an automatic analyser (Konelab 20i; Thermo Fisher Scientific, Vernon Hills, Ill.) at weeks 4 and 10 post-Nx.
Salt-sensitive hypertension was induced by co-administration of L-NAME 70 mg/l in drinking water together with 8% NaCl in chow food (High Salt Diet, HSD) for 10 days. GP1 (100 mg/kg/day) was added or not into the food. Control experiments included vehicle (control), L-NAME or high salt (HSD) alone. Systolic blood pressure (expressed as mmHg) was estimated in the last 3 days of treatment.
After assessment of cardiac hemodynamics, the heart was removed, and the atria and the ventricles were separated and weighed individually. A section of the left ventricle was immersed in Bouin fixative solution. After fixation, the sections were dehydrated and embedded in paraffin. From these sections, 5-m thick histologic slices were obtained and were stained with Sirius Red. For the measurement of cardiac collagen density, slides were examined and photographed under a light microscope (Zeiss) at 40× magnification. Collagen content was calculated as percentage of collagen area to total area of the image. Perivascular collagen was excluded from the analysis.
Frozen mid-LV sections are thawed at room temperature (30 min), immersed in acetone, rinsed in PBS (1×) and immersed in BSA (10 min each). Slides are then incubated with primary rabbit anti-human collagen-I Ab (Abcam ab 34710) (dilution 1/1000) and primary goat anti-human collagen-III Ab (Rnd NBP1 26547) (dilution 1/500) for 1 hour. Thereafter, slides are rinsed three times in PBS (1×) before being incubated with secondary antibodies donkey anti-mouse coupled with FITC (Jackson immunosearch 715-095-151) and donkey anti-goat coupled with Cy3 (Interchim A50-201D3) (dilution 1/400). After three rinses in PBS (1×), slides are mounted with a cover slip on a vecatshield+DAPI medium (Vector Laboratories). A minimum of 8/slide microscopic photographs (×20) were taken from Axiocam-Z1 (Zeiss) fluorescence microscope and analyzed with Image Pro-plus Software. Results are shown as mean±esm.
1) Western-Blot Analysis
Total protein aliquots of 20 μg were prepared from cardiac homogenates and electrophoresed on SDS polyacrylamide gels and transferred to Hybond-c Extra nitrocellulose membranes (Amersham Biosciences). Membranes were incubated with primary antibodies for: NGAL (Abcam; dilution 1:500), Collagen type III (Santa Cruz; dilution 1:500), a-SMA (Sigma; dilution 1:1000), CTGF Abcam; dilution 1:500), GDF-15 (Abcam; dilution 1:500), fibronectin (Millipore, 1:500), Galectin-3 (Thermo, 1:1000), Cardiotrophin-1 (Abcam, 1:500), osteopontin (Santa Cruz, 1:1000), cd3 (Abcam, 1:500), cd68 (Abcam, 1:500), cd80 (Santa Cruz, 1:500) and β-actin (Sigma; dilution 1:1000) as a loading control. After washing, the blots were incubated with peroxidase-conjugated secondary antibody, and binding revealed by ECL chemiluminescence (Amersham). After densitometric analyses, optical density values were expressed as arbitrary units. Results are expressed as an n-fold increase over the values of the control group in densitometric arbitrary units.
2) ELISA
NGAL, IL6 and collagen type I concentrations were measured in cardiac tissue and cell supernatants, respectively, by ELISA according to the manufacturer's instructions (R&D Systems).
3) Proliferation
Cell proliferation was assessed using the MTT Proliferation Assay (Sigma).
4) Gene Expression Analysis
Frozen tissues (kidneys, heart) were homogenized in TRIzol (Life Technologies, 15596018) using FastPrep beads (MP-Bio, 6913-100). cDNAs were generated using the Superscript II reverse transcriptase kit (Invitrogen, 18064022), and qPCR was performed as previously described. Briefly, transcript levels were analysed in a CFX396 apparatus (Biorad). The reactions were performed in duplicate for each sample using the IQ SYBR Green supermix Kit (Biorad, 170-8882). To normalize gene expression, the geometric mean of multiple internal reference genes were used (RS16, Ubc, Hprt and Gapdh for mice experiments). Values in control conditions were set as 1 for each gene. The sequences of the specific primers are detailed in Table A.
Data are presented as the means±SEM. Student's t test (2-tailed) was used to compare paired groups of independent samples. ANOVA with Bonferroni adjustment for post-hoc tests was used for multiple comparisons.
The inhibitory activity of the compounds was evaluated on the NGAL-induced IL6 secretion (NGAL 10 ng/ml) in human cardiac fibroblasts. Among 32 compounds obtained by screening, 2 compounds GPZ614741 and GPZ058225 were selected since they inhibited NGAL-induced IL6 secretion (panel A), Col 1 secretion (panel B), NGAL-induced profibrotic marker (col1, col III, fibronectin, Gal3, OPN) synthesis (panel C) and aldosterone-induced profibrotic marker (Col1, CT-1, or IL6) synthesis (panel D). Results are shown on
Inhibitory activities of 23 second generation compounds derived from GPZ614741 and GPZ058225 were evaluated on the NGAL-induced IL6 secretion (NGAL 10 ng/ml) in human cardiac fibroblasts. Results are shown in table 2a and table 2b.
Identified compounds are as efficient as GPZ614741 and GPZ058225 while other tested compounds have lost their inhibitory activity.
Four candidates selected by virtual screening in the Off-patent Drug database compiled by Greenpharma were evaluated for inhibition of NGAL-induced cell proliferation (NGAL 10 ng/ml) in human cardiac fibroblasts. Results are shown on
The drug candidates were further evaluated for NGAL- or aldo-modulated inflammatory or profibrotic markers expression. Results are shown on
Results are shown on
As shown on
As shown on
Results are shown on
As shown on
Results are shown on
As shown on
Results are shown on
As shown on
As shown on
ADME-Toxicity panel showed that GPZ614741 showed no toxicity for hepatocytes (MTT up to 0.1 mM) nor cardiomyocytes (hERG predictor assay). The PPB was low and fully stable to acidic pH. It was also perfectly soluble in aqueous buffers and partially processed by CYP3A4. On the other hand, it was very sensitive to microsomes degradation (2.2% left after 2 h). The ADME-Toxicity panel showed that GPZ058225 had little hepatotoxicity (>0.1 mM) or cardiotoxicity (it did not block hERG channel). Regarding its stability, GPZ058225 was very stable to degradation by microsomes and to digestive content. It also bound to plasma proteins within acceptance range. It had mild solubility problems (only 63% in the solubility test) and CYP3A4 isoform seemed to be involved in its processing (inhibited the enzyme activity in a competition assay by 32%).
The Bi—CaCo2 assay showed that permeability of GPZ058225 through the intestinal epithelia was quite high (equivalent to the reference compound used).
Results are shown on
As shown in
Results are shown on
As shown in
Results are shown on
As shown in
Results are shown on
As shown on
Results are shown on
As shown on
| Number | Date | Country | Kind |
|---|---|---|---|
| 19305259.4 | Mar 2019 | EP | regional |
| 19305665.2 | May 2019 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/056077 | 3/6/2020 | WO | 00 |
